{"id":898973,"date":"2025-10-22T16:11:38","date_gmt":"2025-10-22T20:11:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"modified":"2025-10-22T16:11:38","modified_gmt":"2025-10-22T20:11:38","slug":"arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","title":{"rendered":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"},"content":{"rendered":"
\n

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.<\/p>\n

The presentation details are as follows:<\/p>\n

\n Title<\/strong>: Preclinical Activity of ARV-806, a PROTAC KRAS G12D Degrader
Presentation Type<\/strong>: Poster presentation
Poster Number<\/strong>: B107
Session<\/strong>: Poster Session B
Date<\/strong>: October 24, 2025
Time<\/strong>: 12:30-4pm ET<\/p>\n

The full abstract can be accessed via the AACR-NCI-EORTC online program<\/a>.<\/p>\n

\n About ARV-806<\/strong>
\n
ARV\u2011806 is a novel, investigational PROTAC degrader designed to selectively target and degrade mutant Kirsten rat sarcoma (KRAS) G12D. KRAS<\/em> is one of the most frequently mutated human oncogenes and G12D is the most common mutation of the KRAS protein. Therefore, ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and lung cancer. ARV\u2011806 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors harboring KRAS G12D mutations.<\/p>\n

\n About Arvinas
<\/strong>Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+\/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed\/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on\u00a0LinkedIn<\/a> and X<\/a>.<\/p>\n

\n Forward-Looking Statements
<\/strong>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-806 to selectively target and degrade mutant KRAS G12D. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas\u2019 strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201clook forward,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.<\/p>\n

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete clinical development for its product candidates, including ARV-806; risks related to Arvinas\u2019 expectations regarding the potential clinical benefit of our product candidates, including ARV-806; uncertainties relating to regulatory applications and related approval timelines; Arvinas\u2019 ability to protect its intellectual property portfolio; Arvinas\u2019 reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas\u2019 cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release.<\/p>\n

\n Contacts
<\/strong>
\n Investors:
<\/strong>Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com<\/a><\/p>\n

\n Media:
<\/strong>Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The presentation details are as follows: Title: Preclinical Activity of ARV-806, a PROTAC KRAS G12D DegraderPresentation Type: Poster presentationPoster Number: B107Session: Poster Session BDate: October 24, 2025Time: 12:30-4pm ET The full abstract can be accessed via the AACR-NCI-EORTC online program. About ARV-806 ARV\u2011806 is a novel, investigational PROTAC degrader designed to selectively target and degrade mutant Kirsten rat sarcoma (KRAS) G12D. KRAS … <\/p>\n

Continue reading “Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898973","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The presentation details are as follows: Title: Preclinical Activity of ARV-806, a PROTAC KRAS G12D DegraderPresentation Type: Poster presentationPoster Number: B107Session: Poster Session BDate: October 24, 2025Time: 12:30-4pm ET The full abstract can be accessed via the AACR-NCI-EORTC online program. About ARV-806 ARV\u2011806 is a novel, investigational PROTAC degrader designed to selectively target and degrade mutant Kirsten rat sarcoma (KRAS) G12D. KRAS … Continue reading "Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T20:11:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\",\"datePublished\":\"2025-10-22T20:11:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"},\"wordCount\":720,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\",\"name\":\"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=\",\"datePublished\":\"2025-10-22T20:11:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk","og_description":"NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The presentation details are as follows: Title: Preclinical Activity of ARV-806, a PROTAC KRAS G12D DegraderPresentation Type: Poster presentationPoster Number: B107Session: Poster Session BDate: October 24, 2025Time: 12:30-4pm ET The full abstract can be accessed via the AACR-NCI-EORTC online program. About ARV-806 ARV\u2011806 is a novel, investigational PROTAC degrader designed to selectively target and degrade mutant Kirsten rat sarcoma (KRAS) G12D. KRAS … Continue reading \"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T20:11:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","datePublished":"2025-10-22T20:11:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"wordCount":720,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","name":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=","datePublished":"2025-10-22T20:11:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU1MDE2OCM3MjA5MTk1IzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-present-preclinical-data-for-arv-806-a-protac-kras-g12d-degrader-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898973"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898973\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}